Healthcare

Growth Opportunities in Sterile Injectable Outsourcing

Biologics Drive the Future Growth Potential of Sterile Injectable Outsourcing

INDUSTRY
Healthcare

RELEASE DATE
08-Jun-2022
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
PD27-01-00-00-00
SKU
HC03548-NA-MT_26593
Yes
SHARE

Growth Opportunities in Sterile Injectable Outsourcing
Published on: 08-Jun-2022 | SKU: HC03548-NA-MT_26593

Need more details?

$2,450.00

$1,837.50 save 25 %

DownloadLink
Need more details?

Injectables constitute one of the fastest growing segments in the pharmaceuticals space. Many drugs, including biologics, are going off patent in next 3 or 4 years, which will lead to an increase in the demand for generics and biosimilar injectables. The increase in onshoring and nearshoring
of biopharmaceutical products for COVID-19 and next-generation biologics has significantly increased the demand for aseptic fill-and-finish capacity and capabilities to meet the demand from various regions. All these factors have made sterile injectable drug product services outsourcing the most lucrative opportunity for contract development and manufacturing companies (CDMO)s. The sterile injectable outsourcing market is set to expand at a CAGR of 9.4%% from 2021 to 2026.

Accelerated project timeframes have prompted CDMOs to review their approach and consider strategies that support greater agility in fill-and-finish operations. The development and manufacturing of high-potency small molecules, less-soluble drugs, and targeted small molecules have allowed small-molecule CDMOs to showcase their capabilities and expertise to pharmaceutical partners. Similarly, biologic manufacturing requires advanced manufacturing/quality control technologies, equipment and skill sets. Biopharma companies and innovative biotech players are increasingly outsourcing process development and manufacturing to CDMOs that possess excellent technologies and equipment.

In this report, Frost & Sullivan offers:
• Insights through market forecasts
• Analysis by segment: small-molecule FDF and biologic drug product
• Market trends, drivers, and restraints
• CDMOs’ investment and expansion into injectable capacity
• Opportunities that stakeholders can pursue

Author: Surbhi Gupta

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on Sterile Injectables Outsourcing

Growth Opportunities Fuel the Growth Pipeline Engine™

Key Takeaways

Scope of Analysis

Forecast Framework—CDMO

Forecast Methodology—Sterile Injectable Outsourcing

Forecast Assumptions

Key Growth Metrics

Growth Drivers

Growth Restraints

Revenue Forecast

Revenue Forecast by Product Type

Revenue Forecast Analysis

Therapeutic Area Overview

Therapeutic Area Overview (continued)

Supply Chain and the Evolving Role of Vendors

Recent Trends Driving Collaborations & Expansions

Recent Trends Driving Collaborations & Expansions (continued)

Capability Overview of Select CDMOs

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—US (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—Europe

CDMO Acquisitions and Sterile Injectable Capacity Expansion—Europe (continued)

CDMO Acquisitions and Sterile Injectable Capacity Expansion—APAC

Smartification of Injectable Delivery Device

Growth Opportunity 1: Flexible and Modular Aseptic Fill-and-Finish Capabilities

Growth Opportunity 1: Flexible and Modular Aseptic Fill-and-Finish Capabilities (continued)

Growth Opportunity 2: Strategic Partnerships that Provide Integrated Injectable Drug Product and Device Service

Growth Opportunity 2: Strategic Partnerships to Provide Integrated Injectable Drug Product and Device Service (continued)

Growth Opportunity 3: Cold-chain Capabilities that Support Next-gen Biologics

Growth Opportunity 3: Cold-chain Capabilities that Support Next-gen Biologics (continued)

List of Exhibits

Legal Disclaimer

List of Figures
  • Sterile Injectable Outsourcing: Key Growth Metrics, Global, 2021
  • Sterile Injectable Outsourcing: Growth Drivers, Global, 2022–2026
  • Sterile Injectable Outsourcing: Growth Restraints, Global, 2022–2026
  • Sterile Injectable Outsourcing: Revenue Forecast, Global, 2020–2026
  • Sterile Injectable Outsourcing: Revenue Forecast by Product Type, Global, 2020–2026
  • Sterile Injectable Outsourcing: Revenue Share by Therapeutic Area, Global, 2021 and 2026
  • Sterile Injectable Outsourcing: Revenue Share by Technology Type, Global, 2021 and 2026

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

17 Nov 2026   |   Global   |   Frost Radar

Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026

Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...

16 Nov 2026   |   North America   |   Frost Radar

Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026

This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...

03 Nov 2026   |   North America   |   Market Research

Enterprise Imaging Market, United States, 2025–2030

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...

02 Nov 2026   |   Global   |   Market Research

Continuous Glucose Monitoring Market, Global, 2026

The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...

28 Oct 2026   |   Global   |   Frost Radar

Frost Radar™: Health Monitoring Wearable Solutions, 2026

The health monitoring wearables industry is undergoing a profound transformation as competitive advantage shifts from device hardware to integrated digital health ecosystems. Market leaders are differentiating through clinically validated health insights, longitudinal data platforms, AI-enabled anal...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.